Top StoriesMerck's Keytruda, up for new FDA nod, spurs lengthy responses in small cell lung cancerMerck & Co. is awaiting an FDA decision for Keytruda in previously treated small cell lung cancer, and it has new numbers to boost its case. Almost one-fifth of patients in a pooled analysis responded to the PD-1 inhibitor, and those who did saw prolonged benefits. Chi-Med, AstraZeneca's savolitinib helps some Tagrisso-resistant EGFR lung cancer patientsAstraZeneca’s Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med and its MET inhibitor, savolitinib. Apexigen, BMS steal the show with promising I-O combo in pancreatic cancerCalifornia biotech Apexigen said during the annual AACR meeting that a combination of its CD40-activating antibody with Bristol-Myers Squibb’s PD-1 inhibitor Opdivo and chemotherapy shrunk tumors in 20 out of 24 patients with pancreatic cancer. Astellas pads Xospata's AML lead with chemo-beating survival dataAstellas is looking to snap up share with Xospata before a head-to-head rival hits the acute myeloid leukemia scene, and some new survival data could help speed that process along. One year after mammoth lung cancer win, Merck's Keytruda holds its own in tough-to-treat subgroupsAt last year’s AACR annual meeting, Merck’s Keytruda-chemo combo stole the spotlight with stellar lung cancer data. And this year, the company was back to show the regimen's results held up in historically tough-to-treat patient groups. TG Therapeutics' umbralisib shrinks tumors in 52% of lymphoma patientsTG Therapeutics’ PI3K delta inhibitor, umbralisib, put up encouraging phase 2b data in marginal zone lymphoma, shrinking tumors in more than half of the patients followed long enough to be evaluated. Of these patients, nearly one-fifth were in complete remission, that is, their cancer was undetectable after treatment. Bristol-Myers Squibb's Opdivo-Yervoy duo provokes response in rare tumorsBristol-Myers Squibb has found success with its Opdivo-Yervoy combo in treating various common tumors. But it turns out the duo can help some patients with rare tumors, too. Vaccine prevents cancer in mouse models of Lynch syndromePeople with the genetic disorder Lynch syndrome face a more than 70% lifetime risk of developing colorectal cancer, as well as an elevated risk of other cancers. In preclinical studies, a vaccine developed at Weill Cornell lowered cancer risk. The researchers are now planning trials in people.
Resources[Whitepaper] Advanced HDX-MS and Native-MS for Improved Biologic Candidate Selection and DevelopmentDiscussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. [Whitepaper] Workbench for Biomarker and Translational ResearchClinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. [Whitepaper] Meet Our Uncle: 12 Protein Stability Applications on One PlatformDownload this whitepaper to learn more! [Whitepaper] Flow Chemistry For Modern API Development & ManufacturingIs Flow Chemistry right for your API Development? [Whitepaper] Systolic Heart Failure: Real-World Study Using Electronic Health RecordsReal-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. [Whitepaper] Better Market Intelligence With Smart SearchFrom new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. [eBook] 2018 Weekly CompendiumThe Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.
|
